SCHEMBL21029658

SCHEMBL21029658

CC(C)OCC(O)C1CCN(C(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21029649 0.77 SMN1; SMN2 (0.33) SMN1; SMN2
SCHEMBL12257664 0.75 SMN1; SMN2 (0.36) SMN1; SMN2
SCHEMBL22844758 0.74 SMN1; SMN2 (0.32) SMN1; SMN2
SCHEMBL26772002 0.72 SMN1; SMN2 (0.35) SMN1; SMN2
SCHEMBL21263289 0.72 DPP4 (0.30)
SCHEMBL22607277 0.71 HRH3 (0.31)
SCHEMBL408517 0.71
SCHEMBL14769610 0.71
SCHEMBL14199815 0.71
SCHEMBL18488104 0.70 DPP4 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190160176-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2019-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160176-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS HAVCR2, DCTD, POLRMT SMN1; SMN2 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.